Clinical Trial Detail

NCT ID NCT03429101
Title A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer
Recruitment Terminated
Gender female
Phase Phase I
Variant Requirements Yes
Sponsors Spectrum Pharmaceuticals, Inc
Indications

Her2-receptor positive breast cancer

Therapies

Ado-trastuzumab emtansine + Poziotinib

Age Groups: adult senior

Additional content available in CKB BOOST